Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

(2018) C Ricordel et al.   ANNALS OF ONCOLOGY

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

(2018) S Novello et al.   ANNALS OF ONCOLOGY

Clinical Utility of Cell-Free DNA for the Detection ofALKFusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

(2018) Caroline E. McCoach et al.   CLINICAL CANCER RESEARCH

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

(2018) Zhe Yang et al.   CLINICAL CANCER RESEARCH

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

(2018) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations

(2018) Tony S. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

(2018) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

(2018) David R. Spigel et al.   Journal of Thoracic Oncology

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

(2018) Leila Dardaei et al.   NATURE MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

(2018) Satoshi Yoda et al.   Cancer Discovery

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

(2018) Pedro N. Aguiar et al.   JAMA Oncology

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP

(2017) Tomohide Tamura et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

(2017) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

(2017) Dong-Wan Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

(2017) Tony S.K. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

(2017) Zhen Wang et al.   Journal of Thoracic Oncology

OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK + /ROS1 + Non-Small-Cell Lung Cancer

(2017) B. Solomon et al.   Journal of Thoracic Oncology

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

(2017) Sabine Schmid et al.   Journal of Thoracic Oncology

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

(2017) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer

(2017) Surein Arulananda et al.   Journal of Thoracic Oncology

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

(2017) Chee Khoon Lee et al.   Journal of Thoracic Oncology

OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms

(2017) G. Oxnard et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

(2017) Alice T Shaw et al.   LANCET ONCOLOGY

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

(2017) Alice T Shaw et al.   LANCET ONCOLOGY

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

(2017) Vasanthi S. Viswanathan et al.   NATURE

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting

(2017) Amy P. Abernethy et al.   PLoS One

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

(2017) Ken Uchibori et al.   Nature Communications

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

(2017) Michaël Duruisseaux et al.   Oncotarget

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

(2017) Rafael Rosell et al.   Lancet Respiratory Medicine

Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply

(2017) Christina Fitzmaurice et al.   JAMA Oncology

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) S. Novello et al.   ANNALS OF ONCOLOGY

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer

(2016) Solange Peters et al.   CANCER TREATMENT REVIEWS

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

(2016) Sen Zhang et al.   CLINICAL CANCER RESEARCH

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

(2016) Shirish M. Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

(2016) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

(2016) M.-J. Ahn et al.   Journal of Thoracic Oncology

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

(2016) Scott N Gettinger et al.   LANCET ONCOLOGY

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

(2016) Dong-Wan Kim et al.   LANCET ONCOLOGY

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

(2016) Glenwood Goss et al.   LANCET ONCOLOGY

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

(2016) Yong Jia et al.   NATURE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

(2015) C. Zhou et al.   ANNALS OF ONCOLOGY

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

(2015) Helen Y. Zou et al.   CANCER CELL

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

(2015) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

(2015) Weijing Cai et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

(2015) Z. Piotrowska et al.   Cancer Discovery

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells

(2015) Shigeki Nanjo et al.   Oncotarget

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

(2015) Collin M. Blakely et al.   Cell Reports

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

(2015) Gouji Toyokawa et al.   Oncology Research and Treatment

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

(2015) Helena A. Yu et al.   JAMA Oncology

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

(2014) Tatsushi Kodama et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

(2014) R. Katayama et al.   CLINICAL CANCER RESEARCH

Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

(2014) Ted W. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

(2013) S. Dearden et al.   ANNALS OF ONCOLOGY

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

(2013) Tianhong Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

(2013) Silvy Laporte et al.   BMJ Open

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

(2012) A. Inoue et al.   ANNALS OF ONCOLOGY

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

(2012) Andrew J. Weickhardt et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation

(2010) M. L. Sos et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

(2010) Samuel Murray et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR

(2008) Anja Michalczyk et al.   BIOORGANIC & MEDICINAL CHEMISTRY

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA